Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8690 in Moderately to Severely Active Ulcerative Colitis
NCT07463183Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Primary completion
- Oct 2027
- Countries
- 11
01
Overview
A Phase 2 trial of MK-8690 in ulcerative colitis (UC), sponsored by Merck & Co.. Started Mar 2026; status: recruiting.
02
Drugs
MK-8690
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07463183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463183.